Everything below concerns GHRH. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-13. Numbers and descriptions here follow the published literature rather than marketing material.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
| Property | Value | Notes |
|---|---|---|
| Duration with linker | Several days | Reported in early human work |
| Duration without linker | Tens of minutes | Short plasma residence |
| Albumin attachment site | Cysteine-34 | Covalent maleimide reaction |
| Primary receptor | Pituitary GHRH receptor | Stimulates growth hormone release |
| Downstream marker | Insulin-like growth factor 1 | Indirect measure of activity |
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
The emu has a prominent place in Australian Aboriginal mythology, including a creation myth of the Yuwaalaraay and other groups in New South Wales who say that the sun was made by throwing an emu's egg into the sky; the bird features in numerous aetiological stories told across a number of Aboriginal groups. One story from Western Australia holds that a man once annoyed a small bird, who responded by throwing a boomerang, severing the arms of the man and transforming him into a flightless emu. The Kurdaitcha man of Central Australia is said to wear sandals made of emu feathers to mask his footprints. Many Aboriginal language groups throughout Australia have a tradition that the dark dust lanes in the Milky Way represent a giant emu in the sky. Several of the Sydney rock engravings depict emus, and the birds are mimicked in Indigenous dances. Hunting emus, known as kari in the Kaurna language, features in the major Dreaming story of the Kaurna people of the Adelaide region about the ancestor hero Tjilbruke. The emu is popularly but unofficially considered as a faunal emblem – the national bird of Australia. It appears as a shield bearer on the Coat of arms of Australia with the red kangaroo, and as a part of the Arms also appears on the Australian 50-cent coin. It has featured on numerous Australian postage stamps, including a pre-federation New South Wales 100th Anniversary issue from 1888, which featured a 2 pence blue emu stamp, a 36-cent stamp released in 1986, and a $1.35 stamp released in 1994.
=== Ifosfamide toxicity === Another use of methylene blue is to treat ifosfamide neurotoxicity. Methylene blue was first reported for treatment and prophylaxis of ifosfamide neuropsychiatric toxicity in 1994. A toxic metabolite of ifosfamide, chloroacetaldehyde (CAA), disrupts the mitochondrial respiratory chain, leading to an accumulation of nicotinamide adenine dinucleotide hydrogen (NADH). Methylene blue acts as an alternative electron acceptor, and reverses the NADH inhibition of hepatic gluconeogenesis while also inhibiting the transformation of chloroethylamine into chloroacetaldehyde, and inhibits multiple amine oxidase activities, preventing the formation of CAA. The dosing of methylene blue for treatment of ifosfamide neurotoxicity varies, depending upon its use simultaneously as an adjuvant in ifosfamide infusion, versus its use to reverse psychiatric symptoms that manifest after completion of an ifosfamide infusion. Reports suggest that methylene blue, up to six doses a day, has resulted in improvement of symptoms within 10 minutes to several days. Alternatively, it has been suggested that intravenous methylene blue every six hours for prophylaxis during ifosfamide treatment in people with history of ifosfamide neuropsychiatric toxicity. Prophylactic administration of methylene blue the day before initiation of ifosfamide, and three times daily during ifosfamide chemotherapy has been recommended to lower the occurrence of ifosfamide neurotoxicity.
Prior to the outbreak of the civil war in 1991, the roughly 53 state-owned small, medium and large manufacturing firms were foundering, with the ensuing conflict destroying many of the remaining industries. However, primarily as a result of substantial local investment by the Somali diaspora, many of these small-scale plants have reopened and newer ones have been created. The latter include fish-canning and meat-processing plants in the northern regions, as well as about 25 factories in the Mogadishu area, which manufacture pasta, mineral water, confections, plastic bags, fabric, hides and skins, detergent and soap, aluminium, foam mattresses and pillows, fishing boats, carry out packaging, and stone processing. In 2004, a US$8.3 million Coca-Cola bottling plant also opened in the city, with investors hailing from various constituencies in Somalia. Foreign investment also included multinationals including General Motors and Dole Fruit.
On 5 January 2023, McDonald's closed its restaurants in Kazakhstan, believed to be due to supply issues after McDonald's prohibited the franchise owner from purchasing burger patties from Russia due to the Russo-Ukrainian war, with its restaurants, operated by Food Solutions KZ, later rebranded to My otkryty. Since August, the network had operated under different names, based on the names of company employees. On November 23, they were rebranded to I'm. Vkusno i tochka will not operate under its brand in Kazakhstan due to the terms of the contract with McDonald's. However, Vkusno i tochka applied to register its brand name.
Sources: en.wikipedia.org
Discussions of radon concentrations in the environment refer to 222Rn, the decay product of uranium and radium. While the average rate of production of 220Rn (from the thorium decay series) is about the same as that of 222Rn, the amount of 220Rn in the environment is much less than that of 222Rn because of the short half-life of 220Rn (55 seconds, versus 3.8 days respectively). Radon concentration in the atmosphere is usually measured in becquerel per cubic meter (Bq/m3), the SI derived unit. Another unit of measurement common in the US is picocuries per liter (pCi/L); 1 pCi/L = 37 Bq/m3. Typical domestic exposures average about 48 Bq/m3 indoors, though this varies widely, and 15 Bq/m3 outdoors. In the mining industry, the exposure is traditionally measured in working level (WL), and the cumulative exposure in working level month (WLM); 1 WL equals any combination of short-lived 222Rn daughters (218Po, 214Pb, 214Bi, and 214Po) in 1 liter of air that releases 1.3 × 105 MeV of potential alpha energy; 1 WL is equivalent to 2.08 × 10−5 joules per cubic meter of air (J/m3). The SI unit of cumulative exposure is expressed in joule-hours per cubic meter (J·h/m3). One WLM is equivalent to 3.6 × 10−3 J h/m3. An exposure to 1 WL for 1 working-month (170 hours) equals 1 WLM cumulative exposure. The International Commission on Radiological Protection recommends an annual limit of 4.8WLM for miners. Assuming 2000 hours of work per year, this corresponds to a concentration of 1500 Bq/m3. 222Rn decays to 210Pb and other radioisotopes. The levels of 210Pb can be measured.
== Tissue distribution == CRF1 is expressed widely throughout both the central and peripheral nervous systems. In the central nervous system, CRF1 is particularly found in the cortex, cerebellum, amygdala, hippocampus, olfactory bulb, ventral tegmental area, brainstem areas, paraventricular hypothalamus, and pituitary. In the pituitary, CRF1 stimulation triggers the activation of the POMC gene, which in turn causes the release of ACTH and β-endorphins from the anterior pituitary. In the peripheral nervous system, CRF1 is expressed at low levels in a wide variety of tissues, including the skin, spleen, heart, liver, adipose tissue, placenta, ovary, testis, and adrenal gland. In CRF1 knockout mice, and mice treated with a CRF1 antagonist, there is a decrease in anxious behavior and a blunted stress response, suggesting that CRF1 mechanisms are anxiogenic. However, the effect of CRF1 appears to be regionally specific and cell-type specific, likely due to the wide variety of cascades and signaling pathways activated by the binding of CRF or CRF-agonists. In mice, offspring born to CRF1 -/- knockout mothers typically die within a few days of birth from lung dysplasia, likely due to low glucocorticoid levels. In the central nervous system, CRF1 activation mediates fear learning and consolidation in the extended amygdala, stress-related modulation of memory formation in the hippocampus, and brainstem regulation of arousal.
Over the next two years, Raymond worked on a colossal project that he considered to be his life’s work: La Basilique de Sainte Sophie (Αγία Σοφία) de Constantinople (The Basilica of Hagia Sophia of Constantinople). This was published in 1933. He used his knowledge of the monument, the work and notes left by his father, the architect Marc Raymond, and a substantial number of photographs of the inside of the building. The undeniable originality of the drawings (ink, watercolour, gold-leaf and silver paintings) is that they represent Hagia Sophia before the Muslims covered it with lime mosaics. Only one drawing of Hagia Sophia, relating to the period when Alexandre Raymond took on his work, 1931, existed. The entire work totals some 88 representations of various sizes. The drawings are complemented by the text describing Hagia Sophia (Αγία Σοφία) written by Procopius of Caesarea, the anonymous text of the Holy Wisdom (also known as Holy Sophia, Divine Wisdom), and a historic and descriptive text from the author.
=== Proposed amalgamation === By early May 2026, several district and regional councils in Northland, Taranaki, the West Coast, Waikato, the Bay of Plenty, Wellington Wairarapa, Hawke's Bay and Southland Regions were discussing options to merge into unitary authorities as part of the Sixth National Government's policy of "simplifying" local government. On 5 May, the Local Government Minister Simon Watts and the RMA Reform Minister Chris Bishop issued local councils with a three-month timeframe to come up with amalgamation plans under the new "Head Start" approach. These amalgamation plans replaced the earlier proposed "combined territorial boards" and would be assessed by the newly-established Ministry for Cities, Environment, Regions and Transport (MCERT). The Government's 2026 amalgamation ultimatum received support from several local government leaders including Mayor of Nelson Nick Smith, Mayor of Southland Rob Scott, Mayor of Timaru Nigel Brown, Mayor of South Wairarapa Dame Fran Wilde, Mayor of Whangārei Ken Couper, Mayor of New Plymouth Max Brough, and Mayor of Invercargill Tom Campbell. By contrast, Mayor of Gore Ben Bell and Mayor of Rotorua Tania Tapsell expressed reservations about merger and the short time-frame. Meanwhile Mayor of Tasman Tim King preferred that the central government decide the local government model rather than delegating it to local councils.
== Transcript variants == Transcription of C3orf62 produces 5 alternatively spliced variants and 1 unspliced form. Of the four splice variants, two of them are protein coding, one is nonsense meditated decay, and one is a retained intron. QIAGEN denotes the following as transcription factor binding sites in the C3orf62 promoter: TFCP2, Pax-6, p53, MyoD, YY1, Ik-2, AREB6, IRF-7A3.
Sources: en.wikipedia.org
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.
The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.
Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.